A study to characterize the humoral and cellular response following simultaneous immunization with a neo-antigen (KLH) and a recall antigen (tetanus) in healthy volunteers.

Condition: Healthy Volunteers
Sponsor: Centre for Human Drug Research (Netherlands) 
Phase 4

NCT02980198

A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis

Condition: Dermatomyositis
Sponsor: Neovacs
Phase 2 

NCT02947854

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Condition: Healthy Volunteers
Sponsor: PCI Biotech
Phase 1 

NCT02800811

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

First-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.

Condition: Healthy Volunteers
Sponsor: OSE Immunotherapeutics
Phase 1 

Relates to J Immunol. 2016 Dec 15;197(12):4593-4602. Epub 2016 Nov 14.

NCT02745756

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Conditions: Neuroblastoma, Nerve Tissue Neoplasms
Sponsor: H. Lee Moffitt Cancer Center & Research Institute
Collaborator: All Childrens Hosp Johns HopkinsMedicine 
Phase 1 

NCT02754362

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose (Poly-ICLC) and bevacizumab in adults with recurrent glioblastoma.

Conditions: Glioblastoma, Glioma
Sponsor: New York University School of Medicine
Collaborator:  Mount Sinai Hospital, New York
Phase 2 

NCT00558051

Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer

Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Sponsor: Pawel Kalisnki, Universiy of Pittsburgh
Phase 1

Relates to JIC Article April 2016

NCT02665364

Study of IFN-K in Systemic Lupus Erythematosus

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Sponsor: Neovacs
Phase 2 

NCT02579252

24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer's Disease (ADAMANT)

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase 2 

NCT02576145

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

Immune Response to Neoantigen and Recall Antigen in Pediatric Renal Transplant Recipients Treated With the IL-2R Alfa Monoclonal Antibody, Daclizumab (Zenapax®)

Sponsor: Hoffman-La Roche
Condition: Kidney Transplantation
Phase 4